OptiBiotix Health PLC Manufacturing agreement for SlimBiome® (2922M)
January 07 2019 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 2922M
OptiBiotix Health PLC
07 January 2019
7 January 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Manufacturing, supply and profit sharing agreement for
SlimBiome(R)
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it has entered into an exclusive
manufacturing and supply agreement with Zeon Lifesciences Ltd
("Zeon"). The agreement grants Zeon an exclusive license to
manufacture and supply OptiBiotix's SlimBiome(R) weight management
technology in India, in return for 50% of the profit.
The agreement optimises the supply chain in Southern Asia by
leveraging Zeon's purchasing power, manufacturing efficiencies and
partner network to scale up the manufacture and supply of
SlimBiome(R). Under the terms of the agreement, Zeon will cover the
cost for the registration of SlimBiome(R) and any finished product
containing Slimbiome(R) with the Food Safety and Standard Authority
of India (FSSAI).
This agreement is an important step in meeting the needs of
major Indian and global corporates for SlimBiome(R), and
SlimBiome(R) containing products, in the large consumer markets of
India and Southern Asia. This business to business (B2B) strategy
brings OptiBiotix's innovative science together with partner's
expertise and market reach to create multiple product opportunities
to serve consumer healthcare markets around the world.
Zeon has over 30 years' experience in developing and
manufacturing customised formulations and presentations (spray
dried and dry blended powders, syrups, capsules, tablets, sachets
and diskettes) for the food, herbal, pharmaceutical and
nutraceutical Industry. It is India's leading manufacturer of
nutraceutical and herbal products with a strong focus on
scientifically researched and clinically backed products which have
the potential to be market leaders. Zeon has NSF Certified and
Certified WHO GMP compliant plants, NABL Accredited quality control
laboratories, and is approved by FSSAI & AYUSH, India. Zeon was
awarded Nutraceutical Manufacturing Company of the Year in 2017 by
The Associated Chambers of Commerce and Industry of India, and Best
Nutraceutical Research Company in 2018 by CMO Asia. Zeon include
major Indian and international healthcare companies such as Danone,
GNC, Decathlon, Sun Pharma and Herbalife amongst its customers.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce this exclusive manufacturing, supply and profit sharing
agreement. We chose Zeon due to their position as India's leading
manufacturer of nutraceutical products, industry reputation,
extensive national and international partner network, and their
expertise in manufacturing high value nutraceutical products. We
believe partnering with Zeon is an important step in optimising the
supply chain to facilitate the needs of existing and new corporate
partners in India and Southern Asia and anticipate further
announcements in due course. We hope the combination of our strong
science and Zeon's local knowledge and manufacturing expertise with
our combined partner network will quickly help bring the benefits
of SlimBiome(R) technology to India's 29.8m obese men and
women."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty five international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRDZLFBKFFBBBV
(END) Dow Jones Newswires
January 07, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024